<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808622</url>
  </required_header>
  <id_info>
    <org_study_id>200-301</org_study_id>
    <nct_id>NCT04808622</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Pharmacodynamic Study of Trans Sodium Crocetinate Utilizing Transcutaneous Oximetry Measurement in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diffusion Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diffusion Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled, pharmacokinetic, pharmacodynamic study.&#xD;
&#xD;
      Subjects will be randomized to TSC or placebo to determine the effect of Trans Sodium&#xD;
      Crocetinate (TSC) on Transcutaneous Oximetry Measurements (tcpO2) following a single&#xD;
      administration of TSC in subjects breathing oxygen (O2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, pharmacokinetic, pharmacodynamic&#xD;
      study of Trans Sodium Crocetinate (TSC) in healthy volunteers. The primary objective is to&#xD;
      determine the effect of TSC on transcutaneous oximetry measurements (tcpO2) following a&#xD;
      single administration of TSC in subjects breathing oxygen (O2).&#xD;
&#xD;
      30 healthy volunteers will be randomized to one of 6 treatment groups, to include 5 TSC doses&#xD;
      (0.5, 1.0, 1.5, 2.0, and 2.5 mg/kg) and placebo normal saline (7 mL). TcpO2 sensors will be&#xD;
      applied to 4 standardized areas on the lower extremity. Subjects will be placed on O2 via&#xD;
      simple face mask at 6 L/minute, and will remain on O2 for 70 minutes prior to study drug&#xD;
      administration. The first 10 minutes will allow for equilibration of O2 levels, and the&#xD;
      subsequent 60 minutes will serve as the baseline period. TcpO2 values and SpO2 will be&#xD;
      recorded every 5 minutes during the above periods. At the end of the 70-minute&#xD;
      equilibration/baseline period, subjects will receive a single IV bolus injection of TSC at a&#xD;
      dose of 0.5, 1.0, 1.5, 2.0 or 2.5 mg/kg, or placebo. Study drug will be administered in a&#xD;
      blinded fashion.&#xD;
&#xD;
      After study drug is administered, subjects will continue on O2 and be evaluated for an&#xD;
      additional 60 minutes, with tcpO2 and SpO2 recorded at 1, 2, and 5 minutes post-dose, and&#xD;
      every 5 minutes thereafter.&#xD;
&#xD;
      Prior to and following study drug administration, PK samples will be obtained pre-dose, and&#xD;
      1, 10, 30, and 90 minutes post-dose.&#xD;
&#xD;
      After the 60 minute post-treatment evaluation period, oxygen will be discontinued and the&#xD;
      tcpO2 sensor electrodes removed. Subjects will remain in the procedure room for an additional&#xD;
      30 minutes to allow for collection of the 1.5-hour PK blood draw and repeat vital signs.&#xD;
      Subjects will remain in the clinic overnight for observation and discharged the following&#xD;
      morning.&#xD;
&#xD;
      Subjects will be contacted by telephone at 48 hours (+ 2 days) for a safety follow up to&#xD;
      assess adverse events and new medications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Actual">March 25, 2021</completion_date>
  <primary_completion_date type="Actual">March 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TcpO2 after study drug administration</measure>
    <time_frame>1 hour after study drug administration</time_frame>
    <description>Determine the dose-response of TSC on tcpO2 following a single administration of TSC in subjects breathing O2</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>TSC 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TSC 0.5 mg/kg given as a one-time IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TSC 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TSC 1.0 mg/kg given as a one-time IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TSC 1.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TSC 1.5 mg/kg given as a one-time IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TSC 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TSC 2.0 mg/kg given as a one-time IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TSC 2.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TSC 2.5 mg/kg given as a one-time IV bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 mL normal saline given as a one-time IV bolus injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trans-Sodium Crocetinate</intervention_name>
    <description>TSC given as a one-time IV bolus injection</description>
    <arm_group_label>TSC 0.5 mg/kg</arm_group_label>
    <arm_group_label>TSC 1.0 mg/kg</arm_group_label>
    <arm_group_label>TSC 1.5 mg/kg</arm_group_label>
    <arm_group_label>TSC 2.0 mg/kg</arm_group_label>
    <arm_group_label>TSC 2.5 mg/kg</arm_group_label>
    <other_name>TSC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo normal saline given as a one-time 7 mL one-time IV bolus injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Sodium Chloride (NaCl)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female, age 18-50&#xD;
&#xD;
          2. Able and willing to lie quietly supine or semi-recumbent for up to 2.5 hours&#xD;
&#xD;
          3. Abstinence from exercise, caffeine, alcohol, nicotine, and a heavy meal prior to&#xD;
             testing on the day of the Treatment Visit&#xD;
&#xD;
          4. Subject is able to communicate effectively with the Investigator and to comply with&#xD;
             all study requirements, restrictions, and directions from the study staff&#xD;
&#xD;
          5. Females of childbearing potential must have a negative blood pregnancy test at&#xD;
             screening and agree to use one of the accepted contraceptive regimens, or a double&#xD;
             method of birth control (e.g. condom and spermicide), during the study and at least 30&#xD;
             days after the last dose of study drug. Females of non-childbearing potential should&#xD;
             be surgically sterile or at least one year post-menopausal.&#xD;
&#xD;
          6. Males who engage in sexual activity that has the risk of pregnancy must agree to use a&#xD;
             double barrier method (e.g. condom and spermicide) and agree not to donate sperm&#xD;
             during the study and for at least 90 days after the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to study medication&#xD;
&#xD;
          2. Pregnant or breastfeeding&#xD;
&#xD;
          3. Current smoker and/or any nicotine use within 4 hours of the start of tcpO2&#xD;
             procedures, to include e-cigarette vaping, snuff, chew, nicotine gum and nicotine&#xD;
             patches&#xD;
&#xD;
          4. Body Mass Index (BMI) &gt; 30&#xD;
&#xD;
          5. Positive test results for HIV-1/HIV-2 Antibodies, Hepatitis B surface Antigen (HBsAg),&#xD;
             or Hepatitis C Antibody (HCVAb)&#xD;
&#xD;
          6. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days&#xD;
             prior to screening&#xD;
&#xD;
          7. Plasma donation within 7 days prior to screening&#xD;
&#xD;
          8. Treatment with an investigational drug within 30 days or 5 times the half-life&#xD;
             (whichever is longer) prior to screening&#xD;
&#xD;
          9. Any skin condition on limbs to be tested that could impair testing (rash, wound, prior&#xD;
             radiation therapy, other skin conditions, per Principal Investigator (PI) discretion)&#xD;
&#xD;
         10. Known cardiovascular disease, including treated or untreated hypertension&#xD;
&#xD;
         11. Significant respiratory disease and/or any other significant medical condition&#xD;
&#xD;
         12. Subject has an acute illness (gastrointestinal infection, influenza, or known&#xD;
             inflammatory process) at the Treatment Visit&#xD;
&#xD;
         13. Urine screen positive for drugs or positive breathalyzer for alcohol (at screening and&#xD;
             enrollment)&#xD;
&#xD;
         14. Concomitant medications used to treat a diagnosed medical condition&#xD;
&#xD;
         15. Subject who, for any reason, is deemed by the Investigator to be unsuitable for the&#xD;
             study; or has any condition that would interfere with the evaluation of tissue oxygen&#xD;
             measurements or PK of the investigational drug; or is otherwise unable to comply with&#xD;
             the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin K Kankam, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altasciences Clinical Kansas Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altasciences Clinical Kansas Inc</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcutaneous oximetry</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trans-sodium crocetinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

